News & Videos - GSK ORD 31 1/4P - Page 2

In den vergangenen Monaten konnten die Bullen in GlaxoSmithKline überzeugen. Jetzt jedoch nehmen die Herausforderungen und damit die Risiken zu....

GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease - Late-breaking data from the daprodustat ASCEND-ND and ASCEND-D trials at the American Society of Nephrology's Kidney Week 2021 confirms the potential for a new oral treatment for patients with anaemia due to chronic kidney disease in both non-dialysis and dialysis settings - Data from five Phase III studies demonstrated that daprodustat improved or maintained...

Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for National Coffee Day Sensodyne® and YouTube Creators Have Teamed Up to Help Coffee-Lovers Find the Joy in their Morning Cup of Joe PR Newswire WARREN, N.J., Sept. 28, 2021 WARREN, N.J. , Sept. 28, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) is raising a cup – or two – of coffee to celebrate enjoying life's simple pleasures without the interruption of tooth...

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. CRSwNP accounts for 2-4% of the US population,...

Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval GSK will also support manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine CVnCoV in 2021 LONDON, UK / TUBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 3, 2021 / GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today...

GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be...

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who progressed on or after a platinum-based regimen. This updated analysis included patients with dMMR endometrial cancer who had measurable disease at baseline...

US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma PR Newswire LONDON, Jan. 21, 2020 Biologics License Application based on results from the pivotal DREAMM-2 study of immunoconjugate targeting B-cell maturation antigen (BCMA) in heavily pre-treated patient population who was refractory to an immunomodulatory drug and a proteasome inhibitor, and refractory or intolerant to an anti-CD38 antibody Belantamab...

Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma PR Newswire LONDON, Dec. 16, 2019 Overall response rate ( ORR ) of 31% with 2.5 mg/kg regimen and no new safety signals in heavily pre-treated patient population who were refractory to an immunomodulatory drug and a proteasome inhibitor, and were refractory or intolerant to an anti-CD38 antibody Data published in The...

STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that its collaborator, GlaxoSmithKline, presented data evaluating SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat (formerly PF-03084014), alone and in combination with GlaxoSmithKline’s investigational anti-B-cell...

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults. Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary...

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer PR Newswire LONDON, Sept. 28, 2019 The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The New England Journal of Medicine, demonstrates that niraparib treatment...

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) Data presented at ESMO 2019 support initiation of phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC PR Newswire LONDON, Sept. 28, 2019 LONDON , Sept. 28, 2019 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell...

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices...

Press Release: 17 April 2019 QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (“C>”s), to be evaluated by GlaxoSmithKline’s C> platform group. Quality control testing for autologous C>’s can be challenging as they are manufactured in small batches and personalised to each patient. However, the C> industry is accustomed to manufacturing therapies in large batches,...

LONDON (Reuters) - GlaxoSmithKline plans to split into two businesses — one for prescription drugs and vaccines, the other for over-the-counter products ......

British pharmaceuticals giant GlaxoSmithKline will combine its consumer health business into a joint venture with US rival Pfizer to create a medical superpower....

Tesaro (TSRO) Alert: Johnson Fistel Investigates Proposed Sale of Tesaro, Inc. to GlaxoSmithKline plc; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Dec. 3, 2018 SAN DIEGO , Dec. 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Tesaro, Inc. (NASDAQ: TSRO) ("Tesaro") breached their fiduciary duties in connection with the proposed sale of the Company to GlaxoSmithKline plc (NYSE: GSK) ("Glaxo")....

NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Avon Products, Inc. (NYSE:AVP), Sanofi (NYSE:SNY), Arch Coal Inc. (NYSE:ARCH), GlaxoSmithKline plc (NYSE:GSK), Chimera Investment Corporation (NYSE:CIM), and PTC Inc. (NASDAQ:PTC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified...

NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sanofi (NYSE:SNY), Amdocs Limited (NASDAQ:DOX), GlaxoSmithKline plc (NYSE:GSK), BT Group PLC (NYSE:BT), Sociedad Quimica y Minera S.A. (NYSE:SQM), and ARMOUR Residential REIT, Inc. (NYSE:ARR), including updated fundamental summaries, consolidated fiscal reporting, and...